TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) will hold a conference call on Wednesday, May 6, 2026 at 8:30 AM ET to discuss first quarter 2026 financial results and provide a business outlook for the rest of 2026.
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) will hold a conference call on Wednesday, May 6, 2026 at 8:30 AM ET to discuss first quarter 2026 financial results and provide a business outlook for the rest of 2026.
Michael S. Weiss, Chairman and CEO, will host. A live webcast and a 30-day audio replay will be available on the company's Investors & Media Events page. Financial results will be released in a press release prior to the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TGTX
On Apr 30, the day this news came out, TGTX closed 0.60% above the previous close.
Data tracked by StockTitan Argus for the Apr 30 session.
Key Figures
- Conference date
- May 6, 2026
- First quarter 2026 results and business outlook call
- Conference time
- 8:30 AM ET
- Scheduled start time for Q1 2026 earnings call
- US dial-in
- 1-877-407-8029
- Domestic access number for the earnings conference call
- International dial-in
- 1-201-689-8029
- International access number for the earnings conference call
- Replay period
- 30 days
- Duration audio recording remains available on company website
- Current price
- $33.58
- Share price before Q1 2026 call announcement
- 52-week range
- $25.28–$46.48
- Price range over the past 52 weeks pre-announcement
- Market cap
- $5,522,019,892
- Equity value before the Q1 2026 call notice
Previous Conferences,earnings Reports
-
Set date and time to discuss Q4 and full-year 2025 results and outlook.
-
Announced Q3 2025 results call with business outlook and 30‑day replay.
-
Scheduled Q2 2025 call outlining results and business update for investors.
-
Announced Q1 2025 call timing and access details with webcast and replay.
-
Outlined Q4 and full-year 2024 call format, logistics, and replay window.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the first quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.